KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) had its price objective reduced by HC Wainwright from $24.00 to $20.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Separately, Needham & Company LLC reiterated a buy rating and set a $35.00 price […]
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Cut to $20 00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Analysts’ price target changes for Friday, May 3rd: Apple (NASDAQ:AAPL) had its target price increased by Canaccord Genuity Group Inc. from $200.00 to $215.00. The firm currently has a buy rating on the stock. Archer Aviation (NYSE:ACHR) had its price target lowered by JPMorgan Chase & Co. from $7.00 to $5.00. They currently have an […]
KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals, Inc. , today announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of.